Thomas Lönngren, Strategic Advisor NDA Group, has been invited to present at the UK Pharmacovigilance Post-Brexit Forum at the Royal College of Physicians, London on Wednesday, 26th April, by the Drug Safety Research Unit.
Dr. Lönngren will be part of an expert panel that will discuss the impact of Brexit on the EU regulatory system and help set the scene of Pharmacovigilance in the UK in relation to Europe after the UK leaves the EU.
To read more about the event and to register click here
